Education
About Us
Working with TipRanks
Follow Us
Journey Medical Corp (DERM)
NASDAQ:DERM
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 16.25%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment driven by the successful launch of Emrosi, strong initial sales, and improved financial metrics. Despite challenges with legacy product revenues and increased SG&A expenses, the company's strategic focus and market reception for Emrosi provide a strong outlook.Company Guidance
During Journey Medical's first quarter 2025 call, the company highlighted the successful launch of Emrosi, an oral rosacea treatment, with initial net product sales of $2 million, contributing to total net product sales of $13.1 million. The company reported a gross margin increase to 64% from 54% year-over-year, despite a rise in SG&A expenses to $10.6 million, primarily due to infrastructure investments for the Emrosi launch. Emrosi's Phase 3 clinical trials, published in JAMA Dermatology, demonstrated statistical superiority over ORACEA, which, combined with recent inclusion in the National Rosacea Society's treatment algorithms, is expected to drive broad clinical adoption. The company has secured 30% market access for commercially insured lives and aims to expand this further. Journey Medical ended the quarter with $21.1 million in cash, and the leadership expressed confidence in becoming sustainably EBITDA positive later in the year.Successful Launch of Emrosi
Journey Medical introduced Emrosi, a new oral rosacea treatment, with $2 million in initial revenue. The launch was supported by strong clinical data, peer-reviewed publications, and inclusion in treatment guidelines.
Increased Gross Margin
Gross margin increased to 64% in Q1 2025 from 54% in the prior period, driven by a favorable product sales mix and lower product costs.
Improved Financial Position
The company reported a reduced net loss of $4.1 million in Q1 2025 compared to $10.4 million in Q1 2024. Cash position increased to $21.1 million from $20.3 million at the end of 2024.
Positive Market Reception for Emrosi
Over 660 unique healthcare providers prescribed Emrosi, and it gained 30% coverage among commercially insured lives.
---
DERM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DERM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $5.97 | $7.10 | +18.93% |
Mar 26, 2025 | $6.14 | $5.92 | -3.58% |
Nov 12, 2024 | $5.45 | $5.12 | -6.06% |
Aug 12, 2024 | $4.22 | $4.82 | +14.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Journey Medical Corp (DERM) report earnings?
Journey Medical Corp (DERM) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Journey Medical Corp (DERM) earnings time?
Journey Medical Corp (DERM) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DERM EPS forecast?
DERM EPS forecast for the fiscal quarter 2025 (Q2) is -0.1.
---